Pharmafile Logo

Competition from within

August 25, 2015 | emerging markets 

Published in eyeforpharma July 29 by Rachel Howard

To what extent can Big Pharma expect to face an increasing challenge from globalizing pharmaceutical companies based in emerging markets?

If we take a look at the top 50 pharmaceutical companies of 2013, they are mainly headquartered in North America (18), the EU (18) or Japan (9). Teva (Israel), CSL (Australia) and Aspen (South Africa) are notable exceptions, with the Indian generic giants Sun and Ranbaxy – which have since merged – the only representation from the ‘BRIC’ markets (Brazil, Russia, India and China). In ten years’ time, will more ‘home-grown’ emerging market companies feature on this list?

In this article, I will explore and compare the directions the domestic pharmaceutical industries of South Korea, China and Brazil have taken in recent years, and consider what threat, if any, each poses to established pharmaceutical companies on a global scale.

Read the full article here http://www.researchpartnership.com/news/2015/07/competition-from-within/

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Quantitative specialist joins Research Partnership, London

Global healthcare market research consultancy Research Partnership has appointed Roy Rogers as a Quantitative Director in their UK offices in London

Webcast

Amplifying the patient voice: How to conduct patient research sensitively to uncover emotional insights

Webcast

The power of a good story: Turn your insights into effective storytelling with data visualisation

Article

How will COVID-19 affect uptake of vaccinations against other diseases?

Podcast

Living With Chronic Illness (Series one)

Webcast

China: How pharma can maximize success in this rapidly changing emerging market

Article

Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma

Infographic

Migraine market snapshot

Webcast

Monitoring the impact of COVID-19 on the market access landscape

Live webinar from Singapore

Digital #marcomms: How to evaluate and optimise marketing activities impacted by COVID-19